📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 17:57
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
35 announcements match the current filters (relevance ≥ 5).
21.9% Revenue Growth in Q1 FY27; New ₹130 Cr Hormonal Facility Commercialized
CORONA Remedies reported a robust Q1 FY27 with revenue growth of 21.9% YoY, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 11.6%. The company successfully commercialized its new ₹130 crore EU-GMP approved hormonal manufacturing facility, which is expected to drive international expansion starting FY29. Volume growth stood at 6.3%, nearly 5x the IPM average of 1.3%, while chronic and semi-chronic therapies now constitute 73.4% of the portfolio. Management expects the new facility to achieve an asset turnover of 2-3x within the next three years.
Confidence: HIGH
What changedThe company has successfully commercialized a major ₹130 crore hormonal facility and outperformed market growth rates across all four key therapeutic segments.
Why it mattersThe new facility represents a significant capacity expansion (capex is ~37% of FY26 revenue) and provides a gateway to high-margin regulated international markets, potentially diversifying the revenue base beyond India.
Q1 Revenue Growth (YoY): 21.9%Hormonal Plant Capex: ₹130 crCapex vs FY26 Revenue: ~36.8%Chronic Portfolio Share: 73.4%Volume Growth (MAT June 2026): 6.3%
📅 Short termThe stock may see positive momentum following the earnings outperformance and the successful commissioning of the new manufacturing facility.
📈 Long termStructural growth is expected as the company enters regulated markets (FY29 target) and leverages its backward integration with La Chandra Pharma Lab for hormonal APIs.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory compliance risks for the EU-GMP facility
- Execution risk in entering competitive international markets
- Price control risks on 'Engine Brands'
Key Highlights
Q1 FY27 revenue grew 21.9% YoY, exceeding the management's stated growth guidance of 15%
Volume growth of 6.3% significantly outperformed the IPM volume growth of 1.3%
Commercialized a new hormonal manufacturing facility with a total capex of ₹130 crores
Chronic and semi-chronic therapies now account for 73.4% of the total product portfolio
Improved market ranking from 29th to 26th in the Indian Pharmaceutical Market (IPM)
👀 What to Watch
Monitor the execution of dossier filings for the EU and other regulated markets scheduled for November-December 2026, as this will dictate the timeline for international revenue contribution.
21.9% Revenue Growth: CORONA Remedies Reports Strong Q1 FY27 with 30.1% PAT Increase
CORONA Remedies reported a strong start to FY27 with standalone revenue growing 21.9% YoY to ₹422.43 cr. Profitability saw a significant boost as PAT rose 30.1% YoY to ₹60.10 cr, supported by EBITDA margins expanding 190 bps to 22.0%. The company improved its market position to 26th in the Indian Pharmaceutical Market (IPM) and commenced commercialization of its new EU-GMP approved Female Hormone facility on June 30, 2026. Integration of the recently acquired Wokadine brand is currently underway to bolster the distribution network.
Confidence: HIGH
What changedCORONA Remedies reported strong Q1 FY27 results exceeding market growth rates and operationalized a new specialized manufacturing facility.
Why it mattersThe company is outperforming the Indian Pharmaceutical Market growth by 1.9 times, and the new EU-GMP facility provides a structural pathway for expansion into regulated international markets.
Revenue (Q1 FY27): ₹422.43 crPAT (Q1 FY27): ₹60.10 crEBITDA Margin: 22.0%YoY Revenue Growth: 21.9%IPM Market Rank: 26th
📅 Short termThe stock is likely to react positively to the double-digit growth in both top and bottom lines and the successful margin expansion.
📈 Long termLong-term growth is supported by therapy leadership in Gynecology (ranked 5th) and the strategic shift toward regulated overseas markets via the new Ahmedabad facility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Dependency on in-licensing partners for high-growth products
- Potential regulatory risks associated with EU-GMP compliance for export expansion
Key Highlights
Revenue from operations increased 21.9% YoY to ₹422.43 cr for the quarter ended June 30, 2026
Net Profit (PAT) grew 30.1% YoY to ₹60.10 cr, with PAT margins improving by 90 bps to 14.2%
EBITDA reached ₹93.1 cr, representing a 33.5% YoY growth with margins at 22.0%
Market ranking improved to 26th in the IPM as of MAT June 2026, up from 29th a year prior
Commercialization of the EU-GMP Female Hormone Manufacturing Facility in Ahmedabad began on June 30, 2026
👀 What to Watch
Investors should monitor the revenue contribution and margin impact of the newly commercialized Female Hormone plant and the progress of Wokadine brand integration in the coming quarters.
21.9% Revenue Growth in Q1 FY27; CORONA Remedies Ranks 26th in IPM
CORONA Remedies reported a strong Q1 FY27 with revenue growing 21.9% YoY to ₹422.4 cr and PAT increasing 30.1% to ₹60.1 cr. The company improved its Indian Pharmaceutical Market (IPM) rank to 26th, driven by its chronic portfolio which now contributes 73.4% of revenue. A significant operational milestone was the June 2026 inauguration of a new EU-GMP certified hormone facility in Gujarat with a capacity of 194 million units. Profitability improved notably with EBITDA margins expanding 190 bps to 22.0%.
Confidence: HIGH
What changedThe company reported strong double-digit growth in Q1 FY27 and successfully commercialized a major new hormone manufacturing facility in Gujarat.
Why it mattersThe shift toward a 73.4% chronic portfolio and the addition of specialized hormone manufacturing capacity are likely to sustain higher margins and support the company's goal of outperforming the broader pharmaceutical market.
Q1 FY27 Revenue: ₹422.4 crQ1 FY27 PAT: ₹60.1 crEBITDA Margin: 22.0%Hormone Facility Capacity: 194 million unitsChronic Portfolio Share: 73.4%Annualized ROCE: 50.2%
📅 Short termThe stock is likely to react positively to the margin expansion and the successful commissioning of the new facility, which provides immediate growth visibility.
📈 Long termThe structural shift from acute to chronic therapies (now 73.4%) and the focus on specialized segments like hormones and infertility treatments position the company for sustainable long-term value creation.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Dependency on in-licensing partners like Ferring Pharmaceuticals for high-growth products
- Regulatory compliance risks at the EU-GMP facility which is critical for export expansion
Key Highlights
Revenue from operations increased 21.9% YoY to ₹422.4 cr for the quarter ended June 30, 2026
EBITDA margins expanded by 190 bps to 22.0%, resulting in a 33.5% YoY growth in EBITDA to ₹93.1 cr
Chronic and sub-chronic therapies now contribute 73.4% of total revenue in Q1 FY27
Inaugurated a new 100,000 sq. ft hormone facility in June 2026 with an annual capacity of 194 million units
Improved market ranking to 26th in the IPM as of MAT June-26, up from 27th in March 2026
👀 What to Watch
Monitor the utilization levels and revenue contribution from the newly inaugurated hormone facility and the progress of entry into regulated overseas markets following the EU-GMP certification.
30.1% PAT Growth: CORONA Remedies Reports Strong Q1FY27 with ₹422.4 Cr Revenue
CORONA Remedies reported a strong start to FY27 with revenue growing 21.9% YoY to ₹422.4 Cr. Profitability improved significantly, with PAT rising 30.1% to ₹60.1 Cr and EBITDA margins expanding by 190 bps to 22.0%. The company improved its market ranking to 26th in the Indian Pharmaceutical Market (IPM) and inaugurated a new EU-GMP approved hormone plant on June 30, 2026. Integration of the recently acquired brand Wokadine is also underway to bolster distribution.
Confidence: HIGH
What changedThe company reported strong Q1FY27 results with double-digit growth and inaugurated a major new manufacturing facility for regulated markets.
Why it mattersThe results confirm CORONA's ability to outpace the broader pharmaceutical market (1.9x IPM growth) and its transition toward higher-margin regulated international markets.
Revenue (Q1FY27): ₹422.4 CrPAT (Q1FY27): ₹60.1 CrEBITDA Margin: 22.0%IPM Rank: 26thRevenue vs FY26 Total: 119.6%
📅 Short termPositive sentiment is expected as the company delivered strong earnings growth and margin expansion alongside a new plant inauguration.
📈 Long termStructural growth is supported by expansion into specialized therapies like Nephrology and CNS, and entry into regulated overseas markets via the new EU-GMP facility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks of acquired brands like Wokadine
- Regulatory compliance risks at the new EU-GMP Gujarat facility
Key Highlights
Revenue from operations increased 21.9% YoY to ₹422.4 Cr for Q1FY27.
PAT grew 30.1% YoY to ₹60.1 Cr, with PAT margins expanding 90 bps to 14.2%.
EBITDA margins improved by 190 bps to reach 22.0% compared to 20.1% in Q1FY26.
Market rank improved to 26th in IPM as of MAT June 2026, up from 29th in MAT June 2025.
Inaugurated and initiated commercialization of a new EU-GMP approved Female Hormone plant on June 30, 2026.
👀 What to Watch
Monitor the revenue contribution and capacity utilization of the newly inaugurated Female Hormone plant and the successful integration of the Wokadine brand.
30.1% PAT Growth: CORONA Remedies Reports Strong Q1 FY27 Results and New Plant Inauguration
CORONA Remedies delivered a robust Q1 FY27, with revenue growing 21.9% YoY to ₹422.4 Cr and PAT increasing 30.1% to ₹60.1 Cr. The company achieved significant margin expansion, with EBITDA margins rising 190 bps to 22.0%, driven by operational efficiencies and brand building. Operationally, the company improved its Indian Pharmaceutical Market (IPM) rank to 26th and inaugurated a new EU-GMP approved Female Hormone Plant in Ahmedabad. Integration of the acquired Wokadine brand is also progressing, supporting the company's focus on core therapies.
Confidence: HIGH
What changedThe company has successfully operationalized a major new manufacturing facility and demonstrated the ability to outpace market growth (1.9x IPM growth) while expanding margins.
Why it mattersThe combination of double-digit revenue growth and margin expansion indicates strong pricing power and brand equity, while the new EU-GMP facility provides a structural pathway for entering regulated international markets.
Q1 FY27 Revenue: ₹422.4 CrYoY PAT Growth: 30.1%EBITDA Margin: 22.0%IPM Rank: 26thRevenue vs FY26 Annualized: ~30% increase over Mar-26 quarter
📅 Short termThe stock is likely to react positively to the margin beat and the news of the new plant commercialization, which provides immediate visibility for volume growth.
📈 Long termThe company is successfully transitioning from a domestic player to a globally-certified manufacturer, with a clear strategy to climb the IPM rankings through both organic growth and brand acquisitions.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks associated with the Wokadine brand acquisition
- Regulatory compliance risks at the new EU-GMP facility
- Dependency on in-licensing partners for high-growth segments
Key Highlights
Revenue from operations grew 21.9% YoY to ₹422.4 Cr for the quarter ended June 30, 2026.
PAT increased by 30.1% YoY to ₹60.1 Cr, with PAT margins improving by 90 bps to 14.2%.
EBITDA margins expanded significantly by 190 bps to reach 22.0% compared to 20.1% in Q1FY26.
Inaugurated and commercialized a new EU-GMP approved Female Hormone Manufacturing Facility on June 30, 2026.
Improved IPM market ranking to 26th as of MAT June '26, up from 29th a year prior.
👀 What to Watch
Investors should monitor the utilization rate and export ramp-up from the newly inaugurated EU-GMP Female Hormone plant, as well as the margin contribution from the integrated Wokadine brand in upcoming quarters.
₹10 Final Dividend Approved at CORONA Remedies 22nd AGM; Chairman Re-appointed for 5 Years
CORONA Remedies concluded its 22nd AGM on July 09, 2026, approving a final dividend of ₹10 per share (100% of face value) for FY 2025-26. Shareholders adopted the FY26 financial statements, which included a March 2026 quarterly revenue of ₹353.09 cr and a net profit of ₹45.33 cr. Key leadership decisions included the re-appointment of Dr. Kirtikumar Mehta as Chairman for a 5-year term and the appointment of Walker Chandiok & Co LLP as Statutory Auditors. The company maintains its focus on expanding into high-growth therapeutic areas like Oncology and CNS while leveraging its EU-GMP certified Gujarat facility.
Confidence: HIGH
What changedThe company has formalized its FY26 financial results, confirmed a significant dividend payout, and secured leadership continuity with a 5-year term for the Chairman.
Why it mattersThe appointment of a 'Big 6' auditor (Walker Chandiok) and the 100% dividend payout signal maturing corporate governance and a commitment to shareholder returns as the company scales its therapeutic presence.
Final Dividend: ₹10 per shareDividend % of Face Value: 100%Chairman Re-appointment Term: 5 yearsMar 2026 Quarterly Revenue: ₹353.09 crMar 2026 Net Profit: ₹45.33 cr
📅 Short termNeutral; the stock may see minor activity related to the dividend approval, but the proceedings are largely in line with standard annual requirements.
📈 Long termPositive governance signal through the appointment of reputable auditors and leadership stability, supporting the company's target growth rate of 16.8%.
Key Highlights
Approved a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26.
Re-appointed Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for a 5-year term.
Appointed Walker Chandiok & Co LLP as the new Statutory Auditors of the company.
Adopted Audited Financial Statements for FY26, following a March quarter revenue of ₹353.09 cr.
Ratified remuneration for Cost Auditors for the upcoming financial year 2026-27.
👀 What to Watch
Investors should monitor the upcoming disclosure of the dividend record date and track the company's execution in regulated overseas markets following its recent capacity expansion to 1.65 billion units.
20% Capacity Increase: CORONA Remedies Starts Production at EU-GMP Hormone Facility
CORONA Remedies has commenced commercial production at its new 1.0 lakh sq. ft. EU-GMP approved hormone manufacturing facility in Bhayla, Ahmedabad. The facility adds an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, representing a ~20% increase in the company's in-house hormone manufacturing capacity. This specialized facility is designed for high-potency hormonal medicines, supporting multiple dosage forms including soft gel capsules and gels. The expansion aligns with the company's strategy to target regulated overseas markets and strengthen its position in the women's healthcare segment, which is one of its core therapeutic areas.
Confidence: HIGH
What changedThe company has transitioned from the construction and validation phase to active commercial production at its specialized hormone manufacturing plant.
Why it mattersHormone manufacturing is a high-barrier segment due to stringent contamination controls and specialized engineering requirements; this facility enables CORONA to scale its high-margin women's health portfolio globally.
New Tablet/Capsule Capacity: 194 million units p.a.New Ointment/Gel Capacity: 1.5 million units p.a.Hormone Capacity Increase: ~20%Facility Area: 1.0 lakh sq. ft.Mar 2026 Revenue: ₹ 353.09 cr
📅 Short termThe commencement of production is a positive milestone that validates the company's execution timeline; expect neutral to positive sentiment as the market factors in future volume growth.
📈 Long termThis is a structural expansion that supports the company's goal of entering regulated overseas markets and expanding into specialized areas like IVF and menopause management over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory compliance risks for EU-GMP standards
- Execution risk in scaling high-potency API handling
- Market competition in the women's healthcare segment
Key Highlights
Annual manufacturing capacity of 194 million tablets/capsules and 1.5 million ointments/gels added.
Facility increases the company's in-house hormone manufacturing capacity by approximately 20%.
New facility spans 1.0 lakh sq. ft. and is EU-GMP approved for regulated market exports.
Supports multiple dosage forms including tablets, soft gel capsules, ointments, and gels within a single ecosystem.
Follows a previous capacity addition of 400 million tablets in December 2025.
👀 What to Watch
Monitor the ramp-up of production at the Bhayla facility and track the company's progress in securing product-specific approvals for regulated overseas markets like the EU.
20% Hormone Capacity Boost: CORONA Remedies Starts Commercial Production at Ahmedabad Facility
CORONA Remedies has commenced commercial production at its new 1.0 lakh sq. ft. EU-GMP approved hormone manufacturing facility in Bhayla, Ahmedabad. The facility adds an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, marking a nearly 20% increase in the company's in-house hormone manufacturing capacity. This specialized plant is designed for high-potency hormonal medicines, supporting multiple dosage forms including soft gel capsules and gels. The expansion is a key step in the company's strategy to target regulated overseas markets and strengthen its position in the high-growth women's healthcare segment.
Confidence: HIGH
What changedCORONA Remedies has transitioned its specialized hormone manufacturing facility from the construction/validation phase to active commercial production.
Why it mattersHormonal products are complex, high-potency medicines that command higher barriers to entry; this expansion scales a high-margin vertical and provides the necessary infrastructure for global market entry.
Annual Tablet/Capsule Capacity: 194 million unitsAnnual Ointment/Gel Capacity: 1.5 million unitsHormone Segment Capacity Increase: 20%Facility Area: 1.0 lakh sq. ft.Latest Quarterly Revenue (Mar 2026): Rs 353.09 cr
📅 Short termThe commencement of production is a positive milestone that validates the company's execution timeline and should support revenue growth in the upcoming quarters.
📈 Long termThis facility is structurally significant as it allows the company to move beyond the domestic market into regulated international territories, potentially improving the overall margin profile through specialized products.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory compliance risks at the EU-GMP facility
- Execution risk in scaling specialized hormonal products
- Dependency on market uptake for high-potency therapies
Key Highlights
New facility adds 194 million tablets/capsules and 1.5 million ointments/gels to annual capacity
Increases total in-house hormone manufacturing capacity by approximately 20%
Facility spans 1.0 lakh sq. ft. and is EU-GMP approved for regulated international markets
Supports specialized dosage forms including tablets, soft gel capsules, ointments, and gels
Integrated 21 CFR-compliant systems and Quality by Design (QbD) principles implemented
👀 What to Watch
Investors should monitor the utilization rate of this new facility over the next 2-4 quarters and watch for any specific export contract wins from regulated markets like the EU, which this facility is now qualified to serve.
Corona Remedies to Hold 22nd AGM on July 9; Recommends ₹10 Dividend for FY 2025-26
Corona Remedies Limited has scheduled its 22nd Annual General Meeting (AGM) for July 9, 2026, via video conferencing. The Board of Directors has recommended a dividend of ₹10 per equity share (100% of face value) for the financial year ended March 31, 2026, which is subject to shareholder approval. The company is currently dispatching physical letters to shareholders who have not registered their email addresses, providing them with the web link to access the full Annual Report for FY 2025-26. Investors are encouraged to update their KYC and bank details to facilitate electronic dividend payments.
Key Highlights
22nd Annual General Meeting scheduled for July 09, 2026, at 11:00 AM IST.
Recommended dividend of ₹10 per equity share of ₹10 each for the financial year 2025-26.
The dividend recommendation was finalized by the Board during their meeting on May 11, 2026.
Annual Report for FY 2025-26 and AGM notice are available on the company's website.
Shareholders must update KYC and bank details with Depository Participants to receive dividends electronically.
👀 What to Watch
Investors should review the FY 2025-26 Annual Report for operational performance and ensure their bank account details are updated with their DP to receive the ₹10 dividend.
CORONA Remedies FY26 Revenue Up 17% to ₹1,403 Cr; 22nd AGM Scheduled for July 09, 2026
CORONA Remedies reported a robust FY 2025-26 with revenue growing 17.28% to ₹1,403.18 crore, significantly outperforming the Indian Pharmaceutical Market (IPM) growth by 859 basis points. The company's PAT surged by 33.44% to ₹199.42 crore, driven by a high-margin chronic portfolio which now contributes 71.94% of total revenue. Strategic acquisitions of brands from Bayer Zydus and Dr. Reddy's have bolstered its presence in fertility and cardiac segments. The company maintains a strong financial profile with a ROCE exceeding 40% and a healthy net cash position.
Key Highlights
Revenue from operations grew 17.28% YoY to ₹1,403.18 crore, while EBITDA rose 22.28% to ₹293.44 crore.
The India business outperformed the IPM by 859 basis points, achieving 17.18% growth compared to the market's 8.59%.
Chronic and sub-chronic therapies now account for 71.94% of revenue, enhancing margin stability and customer retention.
Maintained superior capital efficiency with a Return on Capital Employed (ROCE) of over 40% and operating cash flow to EBITDA conversion of 78%.
Strategic expansion included the acquisition of 7 brands from Bayer Zydus and the Wokadine brand from Dr. Reddy’s Laboratories.
👀 What to Watch
Investors should view the company's consistent market outperformance and high ROCE as strong indicators of execution capability. Monitor the upcoming commissioning of the new hormone facility and the integration of acquired brands for further growth catalysts.
CORONA Remedies Receives EU-GMP Certification for Hormone and OSD Facilities
CORONA Remedies Limited has secured EU-GMP Compliance Certification for its Hormone manufacturing facility and successfully renewed the EU-GMP approval for its Oral Solid Dosage (OSD) unit in Ahmedabad. These approvals follow a successful EUDRA GMP inspection conducted in April 2026. As one of India's top 30 pharmaceutical companies, this accreditation allows CORONA to export its specialized hormone portfolio to highly regulated European and global markets. The move aligns with their strategic vision to serve both domestic and international markets with uniform quality standards.
Key Highlights
New EU-GMP certification granted for the Hormone manufacturing facility in Bhayla, Ahmedabad
Successful renewal of EU-GMP approval for the Oral Solid Dosage (OSD) manufacturing facility
Certifications follow a comprehensive EUDRA GMP inspection completed in April 2026
CORONA Remedies is currently ranked among the Top 30 pharmaceutical corporates in India
Accreditation enables expansion into regulated and semi-regulated global markets for hormone therapies
👀 What to Watch
This is a significant positive development that enhances the company's export capabilities and margin potential; investors should monitor for increased international revenue contributions in upcoming quarters.
Corona Remedies Announces ₹10 Dividend; Sets June 19 Record Date for TDS
Corona Remedies Limited has recommended a final dividend of ₹10 per share (100% of face value) for FY 2025-26. The company has designated June 19, 2026, as the record date for determining shareholder eligibility and for the submission of tax-related documents. Resident shareholders will face a 10% TDS if their dividend exceeds ₹10,000, while a 20% rate applies for missing or unlinked PANs. Non-resident investors may access lower treaty rates by submitting required documentation like Tax Residency Certificates by the deadline.
Key Highlights
Board recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26.
June 19, 2026, is the record date for dividend payment and tax document submission.
TDS of 10% applies to resident individuals with PAN for dividends over ₹10,000.
A higher 20% TDS rate will be applied if PAN is not updated or linked with Aadhaar.
Non-resident shareholders can claim tax treaty benefits by providing digital Form 41 and TRC.
👀 What to Watch
Shareholders should verify their PAN-Aadhaar linking and submit necessary tax exemption forms to the RTA by June 19 to optimize their net dividend receipt.
CORONA Remedies FY26 Revenue up 17% to ₹1,403 Cr, PAT Jumps 33%; Announces ₹10 Dividend
CORONA Remedies reported a robust FY26 performance with revenue growing 17.3% to INR 1,403 crores and adjusted PAT rising 33.4% to INR 199 crores, significantly outperforming the Indian Pharmaceutical Market (IPM). The company improved its industry ranking to 27th and declared a 100% dividend of INR 10 per share. Management has provided a strong outlook for FY27, guiding for 15%+ organic revenue growth and 20%+ PAT growth, supported by new launches in biosimilars and IVF segments.
Key Highlights
FY26 Revenue grew 17.3% to INR 1,403 crores, while Adjusted PAT increased 33.4% to INR 199 crores.
Full-year EBITDA margins improved by 80bps to 20.9%, despite a slight Q4 dip due to expansion investments.
Achieved strong return ratios with RoCE at 41% and RoE at 29.2% for the fiscal year.
Portfolio expansion includes two brands exceeding INR 100 crore and eight brands in the INR 50-100 crore club.
Strategic entry into biosimilars with 4 launches and the establishment of a dedicated IVF taskforce.
👀 What to Watch
Investors should note the company's consistent ability to grow at 2x the industry rate and its high capital efficiency. The stock remains a strong growth-cum-dividend play in the domestic pharmaceutical space.
Corona Remedies Reports Full Compliance in FY26 Annual Secretarial Audit
CORONA Remedies Limited has released its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The independent audit conducted by M/s. Dhara Patel confirms that the company has adhered to all applicable SEBI regulations, including LODR and Insider Trading norms. No deviations, non-compliances, or penalties were reported by the auditor for the period. This clean report underscores the company's commitment to corporate governance and regulatory transparency.
Key Highlights
Achieved 100% compliance with SEBI Regulations for the financial year ended March 31, 2026.
Zero fines or penalties were imposed by SEBI or Stock Exchanges during the review period.
Confirmed maintenance of a Structured Digital Database (SDD) in compliance with Insider Trading regulations.
All related party transactions received prior approval from the Audit Committee.
No instances of statutory auditor resignations or disqualification of directors were recorded.
👀 What to Watch
Investors can take confidence in the company's strong corporate governance and lack of regulatory friction. No immediate action is required as the report contains no adverse findings.
CORONA Remedies FY26 Adj. PAT Jumps 33.4% to ₹199.4 Cr; Outpaces Market Growth by 2x
CORONA Remedies reported a strong financial performance for FY26, with revenue growing 17.3% YoY to ₹1,403.2 Cr and adjusted PAT rising 33.4% to ₹199.4 Cr. The company is significantly outperforming the Indian Pharmaceutical Market (IPM), growing at 2.0x the industry average (17.2% vs 8.6%). Strategic acquisitions of Wokadine from Dr. Reddy's and seven brands from Bayer Zydus, funded via internal accruals, have strengthened its chronic portfolio, which now contributes ~72% of total revenue. With a net cash position and high return ratios (ROCE of 40.8%), the company is well-positioned for its expansion into Eurasian markets following recent EAEU-GMP certification.
Key Highlights
FY26 Revenue grew 17.3% YoY to ₹1,403.2 Cr, while Adjusted PAT surged 33.4% to ₹199.4 Cr.
EBITDA margins expanded by 80 bps to 20.9% for FY26, driven by execution excellence and brand strength.
Strategic acquisitions of Wokadine and 7 Bayer Zydus brands completed using internal accruals, marking entry into the ₹6,481 Cr Povidone Iodine market.
Bhayla facility received EAEU-GMP certification in Jan 2026, unlocking a ~USD 25 billion market opportunity in five Eurasian countries.
Strong return ratios maintained with FY26 ROE at 29.2% and ROCE at 40.8% (excluding one-time labor code impact).
👀 What to Watch
Investors should note the company's superior execution, evidenced by growing at twice the industry rate and maintaining high return ratios while funding M&A through internal cash. The stock warrants a positive outlook given the successful shift to high-margin chronic therapies and the upcoming expansion into Eurasian markets.
Corona Remedies Recommends ₹10 Dividend; Sets June 19 as Record Date
CORONA Remedies has recommended a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26. The company has fixed June 19, 2026, as the record date to determine shareholder eligibility for this payout. Alongside the dividend, the board approved audited financial results for FY26 and announced the appointment of Walker Chandiok & Co LLP as the new statutory auditor for a five-year term. The dividend, if approved at the AGM, will be paid by August 07, 2026.
Key Highlights
Recommended a final dividend of ₹10 per equity share of face value ₹10 (100%)
Fixed June 19, 2026, as the record date for dividend entitlement
Appointed Walker Chandiok & Co LLP as Statutory Auditors for a 5-year term starting FY27
Re-appointed Dr. Kirtikumar Mehta as Chairman for a 5-year term effective April 01, 2027
Dividend payment to be completed on or before August 07, 2026, subject to shareholder approval
👀 What to Watch
Investors seeking the ₹10 per share dividend should ensure they hold the stock prior to the June 19 record date. The transition to a top-tier statutory auditor like Walker Chandiok is a positive indicator for corporate governance.
Corona Remedies Declares ₹10 Dividend and Appoints Walker Chandiok as Statutory Auditor
Corona Remedies has announced its FY26 results along with a significant final dividend of ₹10 per share, representing 100% of the face value. The company is strengthening its governance by appointing Walker Chandiok & Co LLP as its new Statutory Auditor for a five-year period starting FY 2026-27. Leadership stability is maintained with the re-appointment of Dr. Kirtikumar Mehta as Chairman for another five-year term. The record date for the dividend is set for June 19, 2026, with payment expected by August 7, 2026.
Key Highlights
Recommended a final dividend of ₹10 (100%) per equity share for the financial year 2025-26.
Fixed June 19, 2026, as the record date for dividend entitlement with payment by August 07, 2026.
Appointed M/s. Walker Chandiok & Co LLP as Statutory Auditors for a 5-year term (FY 2026-27 to FY 2030-31).
Re-appointed Dr. Kirtikumar Mehta as Chairman for a 5-year term effective April 01, 2027.
Approved audited standalone and consolidated financial results for FY26 with an unmodified audit opinion.
👀 What to Watch
Investors should benefit from the 100% dividend payout and view the transition to a top-tier audit firm as a positive move for corporate governance.
Corona Remedies Recommends ₹10 Dividend and Appoints Walker Chandiok as New Auditor
Corona Remedies has announced a final dividend of ₹10 per share (100% of face value) for FY 2025-26, with the record date set for June 19, 2026. The company reported unmodified audit reports for its standalone and consolidated financial results for the fiscal year ended March 31, 2026. A significant governance update includes the proposed appointment of Walker Chandiok & Co LLP as the new statutory auditor for a five-year term. Additionally, the board has approved the re-appointment of Dr. Kirtikumar Mehta as Chairman for another five-year term starting April 2027.
Key Highlights
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26
Fixed June 19, 2026, as the record date for dividend entitlement with payment by August 07, 2026
Proposed appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for a 5-year tenure
Confirmed unmodified audit reports for both Standalone and Consolidated FY26 financial results
Re-appointed Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for a 5-year term
👀 What to Watch
Investors should track the record date of June 19 to be eligible for the ₹10 dividend and may view the transition to a major audit firm as a positive step for corporate governance.
Corona Remedies Declares ₹10 Dividend, Re-appoints Chairman and Approves FY26 Results
Corona Remedies Limited has announced its audited financial results for the fiscal year ending March 31, 2026, alongside a significant dividend declaration. The Board recommended a final dividend of ₹10 per share (100% of face value), with the record date set for June 19, 2026. In a move to strengthen governance, the company appointed Walker Chandiok & Co LLP as its new statutory auditor for a five-year term. Additionally, Dr. Kirtikumar Mehta has been re-appointed as the Non-Executive Director and Chairman for another five years starting April 2027.
Key Highlights
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26
Set June 19, 2026, as the record date for dividend eligibility, with payment by August 07, 2026
Re-appointed Dr. Kirtikumar Mehta as Chairman for a 5-year term effective April 1, 2027
Appointed Walker Chandiok & Co LLP as Statutory Auditors for five consecutive years starting FY 2026-27
Confirmed unmodified audit reports for both standalone and consolidated financial results for FY26
👀 What to Watch
Investors should ensure they hold shares by the June 19, 2026 record date to qualify for the ₹10 dividend. The transition to a top-tier audit firm and leadership continuity are positive indicators of corporate governance.
CORONA Remedies FY26 PAT Surges 33.4% to ₹199.4 Cr; Revenue Grows 17.3%
CORONA Remedies reported a robust financial performance for FY26, with revenue increasing 17.3% to ₹1,403.2 crore and PAT growing 33.4% to ₹199.4 crore. The company's EBITDA margins improved by 85 bps to 20.9%, driven by operational efficiencies and a strong focus on chronic therapies, which now contribute 71.9% of total revenue. Strategic moves included the acquisition of WOKADINE to enter the ₹648 crore Povidone Iodine market and the relaunch of key brands in women's health and cardiovascular segments. The company also improved its domestic market ranking to 27th, up from 32nd three years ago.
Key Highlights
FY26 Revenue grew 17.3% YoY to ₹1,403.2 Cr, with Q4FY26 revenue rising 20.2% to ₹353.1 Cr.
Full-year PAT increased 33.4% to ₹199.4 Cr, while Q4FY26 PAT surged 43.7% to ₹45.3 Cr.
EBITDA margins expanded by 85 bps to 20.9% for FY26, reflecting strong operating leverage.
Acquired WOKADINE brand via internal accruals, marking entry into the ₹648 Cr Povidone Iodine market.
Chronic therapy segment remains dominant, contributing 71.9% of total revenue in FY26.
👀 What to Watch
Investors should take note of the company's consistent margin expansion and successful brand-building strategy, which has led to two brands crossing the ₹100 Cr MAT milestone. The entry into new markets via EAEU-GMP certification and the WOKADINE acquisition provide clear catalysts for future growth.
